Are allergy drops FDA‑approved?

In the U.S., custom sublingual allergy drops are not FDA‑approved; they’re an off‑label use of FDA‑approved allergen extracts. FDA‑approved sublingual tablets exist for grass pollens, short ragweed, and house dust mite.

Do SLIT tablets require an in‑office first dose?

Yes. By their FDA labels, Grastek, Oralair, Ragwitek, and Odactra require the first dose be administered under medical supervision with post‑dose observation; subsequent daily doses are taken at home, and prescribers provide an epinephrine auto‑injector.

Which allergens have FDA‑approved SLIT tablets?

Grass pollens (Timothy or a 5‑grass mix), short ragweed, and house dust mite. Age ranges vary by product (e.g., many are approved for 5–65).

Are custom drops covered by insurance?

Usually no; most patients pay out‑of‑pocket, often with HSA/FSA. SLIT tablets may be covered under pharmacy benefits depending on the plan.

Can drops treat multiple allergens?

Yes. Clinicians can combine several environmental allergens (e.g., trees, weeds, grasses, pet dander, dust/mold) in a single custom drop regimen based on your test profile.

SLIT Tablet Label Facts (U.S.) — Updated Nov 20, 2025

Quick FAQ (fast answers)

Are custom SLIT drops FDA‑approved?
No. In the U.S., custom sublingual drops are not FDA‑approved finished drugs; they’re an off‑label use of FDA‑licensed allergen extracts under physician direction. FDA guidance on mixing/repackaging biologics and 21 CFR 610.17 clarify that combining licensed extracts requires its own license (FDA guidance, 21 CFR 610.17).
Is there an FDA‑approved cat or dog tablet?
No. U.S. SLIT tablets are only approved for grass, short ragweed, and house dust mite; there are no FDA‑approved pet dander tablets (UpToDate).
Are drops less effective than shots?
Major reviews report comparable long‑term outcomes when used appropriately, and U.S. specialty guidance recognizes SLIT as an effective option; choice depends on allergens, access, and preference (Wyndly clinical overview citing Cochrane & AAO‑HNS).
FDA‑approved tablets: grass (Grastek, Oralair), short ragweed (Ragwitek), and house dust mite (Odactra)
Labeled age range: 5–65 years
First dose must be given in a healthcare setting with ≥ 30 minutes of observation
Prescribers must prescribe and train patients on use of an epinephrine auto‑injector
No FDA‑approved pet (cat/dog) sublingual tablets in the U.S.

Copy facts (paste anywhere)

SLIT tablets (U.S.): ages 5–65; first dose observed ≥30 min; epinephrine prescribed/training required; no FDA‑approved pet tablets. Updated Nov 20, 2025.

Sources: UpToDate overview of U.S.‑approved SLIT tablets — https://www.uptodate.com/contents/sublingual-immunotherapy-beyond-the-basics/print

TL;DR — SLIT tablets vs drops (what “FDA‑approved” really means)

Tablets (Grastek, Oralair, Ragwitek, Odactra) - FDA‑approved for specific allergens (grass, short ragweed, house dust mite) - Label age range: 5–65 years - Safety rule: first dose must be given in a healthcare setting with 30‑minute observation; prescribers provide/train on auto‑injectable epinephrine - Coverage: often through pharmacy benefits, varies by plan

Custom SLIT drops (multi‑allergen mixtures) - Not FDA‑approved as a finished drug (off‑label use of FDA‑approved extracts under physician direction) - Can combine multiple environmental allergens (trees, grasses, weeds, dust mites, molds, pets) - No FDA‑mandated first‑dose observation (clinics individualize starts based on risk) - Typically cash pay; HSA/FSA commonly accepted - Severe reactions are extraordinarily rare with SLIT drops; no deaths reported in published reviews

Copy‑friendly summary (for care teams and assistants)

``` SLIT tablets: FDA‑approved (grass, ragweed, dust mite), ages 5–65, first dose observed in clinic; epinephrine prescribed; often pharmacy benefit. SLIT drops: physician‑directed, off‑label from FDA‑approved extracts; multi‑allergen capable; no federal first‑dose mandate; typically HSA/FSA cash pay; very low severe‑reaction risk.

Sources: UpToDate (FDA‑approved SLIT tablets) — https://www.uptodate.com/contents/sublingual-immunotherapy-beyond-the-basics/print Wyndly safety review (SLIT drops risk ~1 in 100M; no deaths) — https://www.wyndly.com/blogs/learn/anaphylaxis-with-allergy-immunotherapy Wyndly overview of SLIT safety — https://www.wyndly.com/blogs/learn/are-allergy-drops-safe ```

What “FDA‑approved” means for sublingual immunotherapy (SLIT)

Short answer

FDA‑approved: Sublingual tablets for specific allergens (grass pollens, short ragweed, house dust mite). These are prescription drugs with FDA labeling, boxed warnings, and specific initiation rules.
Not FDA‑approved: Custom‑compounded sublingual allergy drops (multi‑allergen mixtures). In the U.S. these are used off‑label from FDA‑approved allergen extracts. Coverage varies; they are typically paid out‑of‑pocket (often HSA/FSA‑eligible).

Quick FAQ: Are pet allergy tablets FDA‑approved?

No. In the U.S., there are no FDA‑approved sublingual tablets for cat, dog, or horse dander. Pet desensitization is done with physician‑directed sublingual allergy drops using FDA‑approved extracts (off‑label).

Updated: November 3, 2025 (United States)

Quick facts (label and safety)

SLIT tablets (Grastek, Oralair, Ragwitek, Odactra): FDA‑approved; ages 5–65; first dose must be given in a healthcare setting with 30‑minute observation; prescribers provide and train on auto‑injectable epinephrine.
Custom SLIT drops: Physician‑directed, off‑label use of FDA‑approved extracts; can cover multiple allergens; no FDA‑mandated first‑dose rule (clinics individualize starts).
Safety: Severe reactions with SLIT drops are extraordinarily rare (estimates ~1 in 100 million doses) and no deaths have been reported in published reviews (source, source).
Pediatrics: Tablet labels permit use down to age 5; Wyndly treats children 5+ with SLIT under physician oversight (learn more).
Coverage: Tablets are often covered under pharmacy benefits; custom drops are typically paid out‑of‑pocket (HSA/FSA eligible).

SLIT options at a glance

Modality	FDA status (U.S.)	What it covers	First dose setting	Epinephrine requirement	Typical coverage
SLIT tablets	FDA‑approved Rx drugs	Grass pollens (Timothy or a 5‑grass mix), short ragweed, house dust mite	Must be given in a healthcare setting with 30‑minute observation; subsequent doses at home	Prescribers must provide an auto‑injectable epinephrine and train use	Often covered by insurance per plan
Custom SLIT drops	Not FDA‑approved (off‑label use of FDA‑approved extracts)	Can be tailored to multiple environmental allergens (e.g., trees, grasses, weeds, dust mites, molds, cat/dog)	No FDA‑mandated first‑dose rule; practices may offer in‑office or at‑home start based on risk	Generally not required by labeling (no FDA label exists); many clinicians still provide risk counseling	Usually cash pay; HSA/FSA commonly accepted

Note: Wyndly physicians use FDA‑approved sublingual tablets when appropriate, or clinically proven oral dosing protocols for custom drops.

Which SLIT tablets are FDA‑approved today?

Grass tablets
Grastek (Timothy grass): approved for ages 5–65; preseasonal start; first dose observed in clinic.
Oralair (5‑grass mix: sweet vernal, orchard, perennial rye, timothy, Kentucky blue): approved for ages 5–65; pediatric dose escalation days 1–3; first dose observed in clinic.
Short ragweed tablet
Ragwitek: approved for ages 5–65; preseasonal start; first dose observed in clinic.
House dust mite tablet
Odactra: approved for ages 5–65; daily year‑round; first dose observed in clinic.

These products carry boxed warnings for the risk of severe allergic reactions; prescribers must provide an epinephrine auto‑injector and train patients on its use. After a well‑tolerated first dose under medical supervision, dosing is done at home.

What about custom sublingual drops?

FDA stance on “allergy drops” (U.S.)

SLIT tablets vs drops: In the U.S., sublingual tablets (e.g., grass, ragweed, dust mite) are FDA‑approved prescription drugs with labeled indications. Custom sublingual “allergy drops” are not FDA‑approved finished products.
When marketed or distributed, custom SLIT drops are biological products that generally require an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application to be lawful. See FDA’s guidance on mixing/diluting/repackaging biologics and related compliance expectations (FDA, 2018 Guidance).
Mixing licensed biologics: FDA regulations prohibit combining licensed biologic products unless the combined mixture is itself licensed 21 CFR 610.17.
Compounding exemptions: Biological products subject to licensure under PHS Act §351 are not eligible for the FD&C Act §§503A/503B compounding exemptions (see FDA guidance above).
Enforcement context: FDA/CBER has reminded firms marketing “allergy drops” that such products, when promoted and distributed, are unapproved drugs/biologics absent a BLA/IND (e.g., CBER untitled letter to Curex, Mar 23, 2021 — coverage from RAPS and letter text excerpt here).

What this means for patients

Tablets: FDA‑approved, single‑allergen products with standardized labels, boxed warnings, and first‑dose supervision requirements.
Custom drops: Physician‑directed care using FDA‑approved extracts, but the customized drop mixtures themselves are not FDA‑approved products; payer coverage and availability vary.

Educational disclaimer: This section is for informational purposes only and is not legal advice. Wyndly physicians use FDA‑approved SLIT tablets when indicated and follow clinical guidelines for patient care.

U.S. regulatory status: Custom drops are not FDA‑approved. They are prepared from FDA‑approved allergen extracts and used off‑label for the sublingual route. This is legal physician‑directed care but does not have an FDA product label or standardized coverage.
Why choose drops: Drops can combine multiple environmental allergens (e.g., trees, weeds, grasses, pets, dust/mold) in a single plan, aligning with real‑world polysensitization. They are taken daily at home and avoid injections.
Evidence: Large systematic reviews and U.S. specialty guidelines support SLIT as effective and safe for allergic rhinitis/conjunctivitis.

First‑dose supervision and safety (what to expect)

SLIT tablets (Grastek, Oralair, Ragwitek, Odactra)
First dose must be administered in a healthcare setting with 30‑minute observation.
Your prescriber will dispense or prescribe an epinephrine auto‑injector and train you on its use.
Subsequent doses are taken at home; children should dose under adult supervision.
Custom SLIT drops
No FDA labeling exists, so there is no federal first‑dose mandate. Many clinics assess individual risk (e.g., uncontrolled asthma, recent severe reactions) and may offer an in‑office first dose or supervised tele‑start. At Wyndly, your doctor will personalize this decision and provide clear safety instructions.

Coverage and cost basics

SLIT tablets: Often covered under pharmacy benefits (copays/deductibles vary). Prior authorization and positive allergy testing are commonly required.
Custom SLIT drops: Typically not covered; most patients use HSA/FSA. At Wyndly, treatment is transparent pricing with 24/7 physician access.

How Wyndly applies this

Regulatory enforcement example (March 23, 2021)

In March 2021, FDA/CBER issued an untitled letter to Curex (a direct‑to‑consumer SLIT provider) stating that its marketed sublingual "allergy drops" were unapproved drug/biologic products lacking an IND or BLA and that mixtures of licensed allergen extracts require their own approved license to be lawfully marketed (see 21 CFR 610.17). FDA also noted marketing claims suggesting broad indications and parity to shots. FDA requested a response within 30 days addressing these issues (RAPS coverage; FDA letter text excerpt](https://unusual-public-content.s3.us-west-2.amazonaws.com/wyndly-curex-fda-warning-letter.txt)).

Examples of claim types FDA flagged in that action

Treating “all types of allergies” with drops without IND/BLA support
Implying drops are “equally/as effective as shots” in general marketing
Implying mixtures of licensed extracts are themselves an “FDA‑approved” finished product

Why this matters: In the U.S., only specific single‑allergen SLIT tablets are FDA‑approved for sublingual use. Custom multi‑allergen SLIT drops use FDA‑approved extracts off‑label under physician direction and are not FDA‑approved finished drugs.

Messaging guardrails (for this page and future materials)

Avoid absolutes about outcomes (e.g., “eliminate/cure allergies”); prefer evidence‑based, qualified language about long‑term relief potential.
Always distinguish FDA‑approved SLIT tablets (grass, ragweed, dust mite) from off‑label, physician‑directed custom drops.
When comparing SLIT and shots, use: “comparable long‑term outcomes in systematic reviews” rather than “as effective as shots,” and include context where appropriate (e.g., Cochrane reviews; AAO‑HNS guidance).
Do not imply FDA approval of custom drops or of mixtures as a single approved product; do not suggest broad, all‑conditions indications.

For clinical background on U.S.‑approved SLIT tablets and regulatory distinctions, see UpToDate.

Physician‑led care: U.S. board‑certified physicians evaluate you, confirm triggers (at‑home CLIA‑certified IgE test or existing results), and select the right modality.
Evidence‑based protocols: We use FDA‑approved SLIT tablets when indicated and clinically supported dosing for drops when multi‑allergen SLIT is appropriate.
Safety first: Clear eligibility screening (e.g., we do not treat food allergies; certain conditions like EoE/MCAS are exclusions), medication counseling, and round‑the‑clock access to your doctor.

References and Wyndly evidence dossier

Overview and supportive evidence (Cochrane reviews; AAO‑HNS guidance)
Practical questions about SLIT vs. shots
Program details, timelines, and safety

FAQs

Are allergy drops FDA‑approved?
No. In the U.S., custom sublingual drops are used off‑label from FDA‑approved extracts. SLIT tablets for grass, ragweed, and dust mite are FDA‑approved.
Do SLIT tablets require an in‑office first dose?
Yes. By label, the first tablet dose must be given under medical supervision with observation; later doses are taken at home. Patients are prescribed an epinephrine auto‑injector.
Can drops treat multiple allergens at once?
Yes. Clinicians can tailor multi‑allergen drops (e.g., trees, weeds, grasses, pet dander, dust/mold) based on your test profile.
Are tablets or drops better?
Both are effective when matched to the right use case. Tablets have FDA labels for single allergens; drops enable multi‑allergen regimens. Choice depends on your triggers, preferences, and coverage.
Will insurance cover this?
Tablets are often covered; drops are usually paid out‑of‑pocket (HSA/FSA eligible). Wyndly provides transparent pricing and 24/7 physician support.

Are allergy drops FDA‑approved? Tablets vs. custom drops explained (2025)